| NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 00078-0675-15 | 00078-0675 | ondansetron hydrochloride | ZOFRAN | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Mar 7, 2018 | May 31, 2022 | No Longer Used |
| 23155-0356-32 | 23155-0356 | Palonosetron Hydrochloride | Palonosetron Hydrochloride | 0.05 mg/mL | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Intravenous | Jun 29, 2021 | Jun 30, 2021 | In Use |
| 43063-0560-04 | 43063-0560 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Apr 4, 2016 | Jan 18, 2021 | No Longer Used |
| 50090-1936-01 | 50090-1936 | Finasteride | Finasteride | 5.0 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Jul 20, 2015 | In Use | |
| 00115-1438-08 | 00115-1438 | Dutasteride | Dutasteride | 0.5 mg/1 | Ancillary Therapy | Protective Agent | 5-alpha Reductase Inhibitor | Oral | Nov 20, 2015 | In Use | |
| 00172-5241-70 | 00172-5241 | Anagrelide Hydrochloride | Anagrelide Hydrochloride | 0.5 mg/1 | Ancillary Therapy | Platelet-Reducing Agent | PDE-3 Inhibitor | Oral | Apr 18, 2005 | Jun 9, 2009 | In Use |
| 63304-0346-05 | 63304-0346 | Ondansetron | Ondansetron | 4.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 10, 2012 | In Use | |
| 00024-5844-01 | 00024-5844 | Sargramostim | Leukine | 500.0 ug/mL | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | Intravenous, Subcutaneous | Dec 1, 1996 | Dec 30, 2021 | No Longer Used |
| 00054-4496-25 | 00054-4496 | Leucovorin Calcium | Leucovorin Calcium | 5.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Feb 22, 1993 | In Use | |
| 53217-0360-01 | 53217-0360 | ondansetron | ondansetron | 8.0 mg/1 | Ancillary Therapy | Antiemetic | 5HT3 Receptor Antagonist | Oral | Jan 18, 2018 | In Use | |
| 69315-0187-25 | 69315-0187 | Leucovorin calcium | Leucovorin calcium | 25.0 mg/1 | Ancillary Therapy | Chemoprotective | Antidote | Oral | Nov 16, 2020 | In Use | |
| 00143-9428-01 | 00143-9428 | FOSAPREPITANT DIMEGLUMINE | FOSAPREPITANT DIMEGLUMINE | 150.0 mg/5mL | Ancillary Therapy | Antiemetic | Substance P/Neurokinin 1 | Intravenous | May 1, 2021 | In Use | |
| 53150-0871-01 | 53150-0871 | Zoledronic Acid | Zoledronic Acid | 4.0 mg/5mL | Ancillary Therapy | Bisphosphonate | Intravenous | Apr 23, 2012 | Dec 31, 2017 | No Longer Used | |
| 00078-0923-61 | 00078-0923 | letrozole and ribociclib | Kisqali Femara Co-pack | 2.5 mg/1, 200.0 mg/1 | Chemotherapy, Hormonal Therapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6, Hormonal | Oral | May 4, 2017 | Aug 31, 2026 | In Use |
| 00078-0916-61 | 00078-0916 | Letrozole and ribociclib | Kisqali Femara Co-pack | 2.5 mg/1, 200.0 mg/1 | Chemotherapy, Hormonal Therapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6, Hormonal | Oral | May 4, 2017 | Aug 31, 2026 | In Use |
| 00078-0909-61 | 00078-0909 | letrozole and ribociclib | Kisqali Femara Co-pack | 2.5 mg/1, 200.0 mg/1 | Chemotherapy, Hormonal Therapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6, Hormonal | Oral | May 4, 2017 | Aug 31, 2026 | In Use |
| 70121-1482-02 | 70121-1482 | carmustine | carmustine | Chemotherapy | Alkylating Agent | Nitrosourea | Intravenous | Oct 22, 2018 | In Use | ||
| 55390-0806-10 | 55390-0806 | Cytarabine | Cytarabine | Chemotherapy | Antimetabolite | Pyrimidine Analog | Intravenous, subcutaneous, intrathecal | Jun 28, 1996 | Jul 31, 2013 | No Longer Used | |
| 54868-5260-02 | 54868-5260 | Capecitabine | Xeloda | 500.0 mg/1 | Chemotherapy | Antimetabolite | Pyrimidine Analog | Oral | Jun 28, 2005 | In Use | |
| 61958-1701-01 | 61958-1701 | Idelalisib | Zydelig | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | PI3K | Oral | Jul 23, 2014 | In Use | |
| 00409-0367-01 | 00409-0367 | Docetaxel | Docetaxel | 20.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Aug 24, 2016 | In Use | |
| 73462-0101-01 | 73462-0101 | Trilaciclib | Cosela | 300.0 mg/20mL | Chemotherapy | Cyclin Dependent Kinase Inhibitor | CDK 4/6 | Intravenous | Feb 12, 2021 | Dec 31, 2028 | In Use |
| 00143-9275-01 | 00143-9275 | Doxorubicin Hydrochloride | Adriamycin | 2.0 mg/mL | Chemotherapy | Antitumor Antibiotic | Anthracycline | Intravenous | Jan 19, 2018 | In Use | |
| 73358-0210-08 | 73358-0210 | Docetaxel Anhydrous | Docetaxel Anhydrous | 10.0 mg/mL | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | Oct 17, 2022 | In Use | |
| 31722-0297-30 | 31722-0297 | IMATINIB MESYLATE | IMATINIB MESYLATE | 400.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | BCR-ABL | Oral | Apr 14, 2025 | In Use |
Found 12250 results — Export these results
Home